Fabienne Hermitte will present : “From transational research to CDx development” – Veracyte BioPharma ATLAS: How to guide Biopharma’s biomarker strategy ? – How to identify predictive and/or toxicity signature ? – CDx development: How to Integrate the new IVDR regulation ?
On wednesday, 27 April at 11h45 AM.
For more information about this event, visit the website
